• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与TACE治疗反应相关的微小RNA：从放射学角度对文献的综述

MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View.

作者信息

Bozzato Alessandro Marco, Martingano Paola, Pozzi Mucelli Roberta Antea, Cavallaro Marco Francesco Maria, Cesarotto Matteo, Marcello Cristina, Tiribelli Claudio, Pascut Devis, Pizzolato Riccardo, Pozzi Mucelli Fabio, Giuffrè Mauro, Crocè Lory Saveria, Cova Maria Assunta

机构信息

Department of Medical, Surgical and Health Sciences, University of Trieste, 34151 Trieste, Italy.

Department of Radiology, ASUGI, Ospedale di Cattinara, 34149 Trieste, Italy.

出版信息

Diagnostics (Basel). 2022 Feb 1;12(2):374. doi: 10.3390/diagnostics12020374.

DOI:10.3390/diagnostics12020374
PMID:35204465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8871153/
Abstract

Hepatocellular Carcinoma (HCC) is the sixth most common cancer in the world. Patients with intermediate stage (Barcelona Clinic Liver Cancer, B stage) hepatocellular carcinoma (HCC) have been able to benefit from TACE (transarterial chemoembolization) as a treatment option. MicroRNAs (miRNAs), i.e., a subclass of non-coding RNAs (ncRNAs), participate in post-transcriptional gene regulation processes and miRNA dysfunction has been associated with apoptosis resistance, cellular proliferation, tumor genesis, and progression. Only a few studies have investigated the role of miRNAs as biomarkers predicting TACE treatment response in HCC. Here, we review the studies' characteristics from a radiological point of view, also correlating data with radiological images chosen from the cases of our institution.

摘要

肝细胞癌（HCC）是全球第六大常见癌症。中期（巴塞罗那临床肝癌分期，B期）肝细胞癌（HCC）患者已能够从经动脉化疗栓塞术（TACE）作为一种治疗选择中获益。微小RNA（miRNA），即非编码RNA（ncRNA）的一个亚类，参与转录后基因调控过程，且miRNA功能障碍与凋亡抵抗、细胞增殖、肿瘤发生和进展有关。仅有少数研究探讨了miRNA作为预测HCC中TACE治疗反应的生物标志物的作用。在此，我们从放射学角度回顾这些研究的特征，并将数据与从我们机构病例中选取的放射影像相关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/518a2faff790/diagnostics-12-00374-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/0eab1dd25743/diagnostics-12-00374-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/40494518fe6b/diagnostics-12-00374-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/f66835bb7813/diagnostics-12-00374-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/95c21643bdd2/diagnostics-12-00374-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/e84e38363299/diagnostics-12-00374-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/b5926659e937/diagnostics-12-00374-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/74e7805f856e/diagnostics-12-00374-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/518a2faff790/diagnostics-12-00374-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/0eab1dd25743/diagnostics-12-00374-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/40494518fe6b/diagnostics-12-00374-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/f66835bb7813/diagnostics-12-00374-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/95c21643bdd2/diagnostics-12-00374-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/e84e38363299/diagnostics-12-00374-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/b5926659e937/diagnostics-12-00374-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/74e7805f856e/diagnostics-12-00374-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/8871153/518a2faff790/diagnostics-12-00374-g008.jpg

相似文献

1
MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View.与TACE治疗反应相关的微小RNA：从放射学角度对文献的综述
Diagnostics (Basel). 2022 Feb 1;12(2):374. doi: 10.3390/diagnostics12020374.
2
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
3
Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.不可切除肝细胞癌患者首次和重复经动脉化疗栓塞术的临床预测系统的验证和评估：一项中国多中心回顾性研究。
World J Gastroenterol. 2020 Feb 14;26(6):657-669. doi: 10.3748/wjg.v26.i6.657.
4
Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.近畿标准B1和B2期肝细胞癌患者经动脉化疗栓塞难治性出现时间
Dig Dis. 2017;35(6):589-597. doi: 10.1159/000480208. Epub 2017 Oct 17.
5
DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.经动脉化疗栓塞术治疗中晚期肝癌——巴西一家癌症中心的初步经验
Cancer Imaging. 2017 Feb 6;17(1):5. doi: 10.1186/s40644-017-0108-6.
6
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.经导管动脉化疗栓塞联合射频消融治疗巴塞罗那临床肝癌分期 A 或 B 期肝细胞癌患者的临床结局改善，无论肿瘤大小：单中心回顾性病例对照研究结果。
BMC Cancer. 2019 Oct 22;19(1):983. doi: 10.1186/s12885-019-6237-5.
7
Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.经肝动脉化疗栓塞术治疗后，介入治疗后白细胞介素 6（IL-6）水平而非治疗前或 IL-6 的动态变化，可作为肝细胞癌早期肿瘤反应的实用标志物。
Oncologist. 2019 Dec;24(12):e1489-e1495. doi: 10.1634/theoncologist.2018-0669. Epub 2019 Jun 27.
8
Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.血浆 microRNA-21、26a 和 29a-3p 作为预测经动脉化疗栓塞治疗肝细胞癌患者治疗反应的标志物。
J Korean Med Sci. 2018 Jan 1;33(1):e6. doi: 10.3346/jkms.2018.33.e6.
9
Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.经动脉化疗栓塞术与射频消融术治疗不可切除的巴塞罗那临床肝癌分期0/A期肝细胞癌的比较：倾向评分匹配法
J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077.
10
Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.肝切除术与经肝动脉化疗栓塞术治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的比较。
Hepatol Int. 2018 Sep;12(5):417-428. doi: 10.1007/s12072-018-9888-4. Epub 2018 Aug 2.

引用本文的文献

1
Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC.肿瘤抑制因子miR-34a：肝癌经动脉化疗栓塞术反应的潜在生物标志物
Cardiovasc Intervent Radiol. 2025 Jan;48(1):26-37. doi: 10.1007/s00270-024-03908-5. Epub 2024 Dec 5.
2
Genetic Alchemy unveiled: MicroRNA-mediated gene therapy as the Artisan craft in the battlefront against hepatocellular carcinoma-a comprehensive chronicle of strategies and innovations.揭开基因炼金术的面纱：微小RNA介导的基因治疗在对抗肝细胞癌前线的精湛技艺——策略与创新的全面记录
Front Genet. 2024 Jun 10;15:1356972. doi: 10.3389/fgene.2024.1356972. eCollection 2024.
3
Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.

本文引用的文献

1
Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.超声造影在 HCC 诊断和局部治疗后肿瘤反应评估中的应用。
Abdom Radiol (NY). 2021 Aug;46(8):3579-3595. doi: 10.1007/s00261-021-03059-y. Epub 2021 Apr 7.
2
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
3
Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.
非编码RNA在肝细胞癌进展中的作用：从经典到新的临床病理发病学意义
Cancers (Basel). 2023 Oct 27;15(21):5178. doi: 10.3390/cancers15215178.
4
Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.治疗前循环miR-221对接受经动脉化疗栓塞的肝细胞癌患者的预测作用
Diagnostics (Basel). 2023 Aug 29;13(17):2794. doi: 10.3390/diagnostics13172794.
5
The long non-coding RNA keratin-7 antisense acts as a new tumor suppressor to inhibit tumorigenesis and enhance apoptosis in lung and breast cancers.长链非编码 RNA 角蛋白-7 反义链作为一种新的肿瘤抑制因子，可抑制肺癌和乳腺癌的肿瘤发生并增强细胞凋亡。
Cell Death Dis. 2023 Apr 25;14(4):293. doi: 10.1038/s41419-023-05802-3.
6
An Insight into the Arising Role of MicroRNAs in Hepatocellular Carcinoma: Future Diagnostic and Therapeutic Approaches.浅析 microRNAs 在肝细胞癌中的涌现角色：未来的诊断和治疗方法。
Int J Mol Sci. 2023 Apr 12;24(8):7168. doi: 10.3390/ijms24087168.
7
Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.miR-223-3p 作为经动脉化疗栓塞治疗肝细胞癌患者的预后标志物的可能用途。
Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4125-4135. doi: 10.31557/APJCP.2022.23.12.4125.
8
Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation.乳糜泻与神经表现：从麸质到神经炎症。
Int J Mol Sci. 2022 Dec 8;23(24):15564. doi: 10.3390/ijms232415564.
9
Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience.手术切除或消融治疗的肝细胞癌患者早期复发的预测因素：单中心经验
Diagnostics (Basel). 2022 Oct 17;12(10):2517. doi: 10.3390/diagnostics12102517.
10
Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis.全身免疫炎症指数与经动脉化疗栓塞术后肝细胞癌患者的生存：一项荟萃分析。
Clin Exp Med. 2023 Oct;23(6):2105-2114. doi: 10.1007/s10238-022-00889-y. Epub 2022 Oct 26.
肝细胞癌预后评分的比较：一项为期10年的单中心经验及当前文献简要综述
World J Hepatol. 2020 Dec 27;12(12):1239-1257. doi: 10.4254/wjh.v12.i12.1239.
4
Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma.循环微小RNA作为肝细胞癌治疗反应和无病生存的生物标志物
Cancers (Basel). 2020 Sep 29;12(10):2810. doi: 10.3390/cancers12102810.
5
Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.miR-1271和磷脂酰肌醇蛋白聚糖-3在评估经导管动脉化疗栓塞术后肝细胞癌患者预后中的价值
World J Clin Cases. 2020 Aug 26;8(16):3493-3502. doi: 10.12998/wjcc.v8.i16.3493.
6
Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization.血清 TSGF 和 miR-214 水平在肝癌患者中的变化及其对经导管动脉化疗栓塞疗效的预测价值。
Ann Palliat Med. 2020 Jul;9(4):2111-2117. doi: 10.21037/apm-20-1224.
7
MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.miR-125b 缺失激活 HIF1α/pAKT 环路，导致肝癌经动脉化疗栓塞耐药。
Hepatology. 2021 Apr;73(4):1381-1398. doi: 10.1002/hep.31448. Epub 2020 Nov 7.
8
Evaluation of liver tumour response by imaging.通过影像学评估肝肿瘤反应。
JHEP Rep. 2020 Apr 28;2(3):100100. doi: 10.1016/j.jhepr.2020.100100. eCollection 2020 Jun.
9
Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.循环中的miR-26a、miR-106b、miR-107和miR-133b可根据肝细胞癌患者对经动脉化疗栓塞术的反应对其进行分层。
Clin Biochem. 2019 Mar;65:45-52. doi: 10.1016/j.clinbiochem.2019.01.002. Epub 2019 Jan 15.
10
Update in global trends and aetiology of hepatocellular carcinoma.肝细胞癌全球趋势与病因学的最新进展
Contemp Oncol (Pozn). 2018;22(3):141-150. doi: 10.5114/wo.2018.78941. Epub 2018 Sep 30.